LL-K8-22

• Target :

  CDK|||Others|||Early 2 Factor (E2F) |||PROTACs|||STAT

• Related Pathways :

  Cell Cycle/Checkpoint|||JAK/STAT signaling|||Others|||Stem Cells|||PROTAC

• Bioactivity :

  LL-K8-22 is a potent, selective, and durable dual degrader of CDK8-cyclin C, demonstrating DC50 values of 2.52 and 2.64 ?M, respectively. This compound effectively suppresses STAT1 Ser 727 phosphorylation and inhibits carcinogenic transcriptional programs driven by E2F and MYC. LL-K8-22 is specifically utilized in research for triple-negative breast cancer (TNBC) [1].

• Molecular Formula :

  C37H43N5O

• Molecular Weight :

  573.77

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C